Moreover, as mentioned above, the dynamic change in lymphocytes and the abundance of lymphocytes in tumor tissues may reflect the change in patients’ antitumor immunity, but we failed to analyze the effect of dynamic circulating lymphocytes on the safety and efficacy of PD-1/PD-L1 inhibitors. This evidence concerns the gene PDCD1 and neoplasm.